37 results
6-K
EX-99.2
ACIU
AC Immune SA
3 Nov 23
Current report (foreign)
7:30am
presented at CTAD 2022 confirmed peripheral target engagement and reduction in CSF total Tau, pTau181 and pTau217, observed after semorinemab
6-K
EX-99.2
ACIU
AC Immune SA
4 Aug 23
Current report (foreign)
7:30am
peripheral target engagement and reduction in CSF total Tau, pTau181 and pTau217, observed after semorinemab treatment but not with placebo. Genentech
6-K
EX-99.1
ACIU
AC Immune SA
26 Jun 23
Current report (foreign)
8:40am
in patients followed for more than 3.5 years 1 Strong and boostable antibody responses 2 Target engagement evidence: 50% reduction in pathological (oligomeric
6-K
EX-99.2
ACIU
AC Immune SA
28 Apr 23
Current report (foreign)
7:30am
signals. At CTAD 2022, Genentech presented CSF and plasma biomarkers. These data confirmed peripheral target engagement and reduction in CSF total Tau
6-K
EX-99.2
v7218c5r66q2sgpbzatv
28 Oct 22
Current report (foreign)
8:00am
6-K
EX-99.3
3ww36sfi 0mwc
28 Jul 22
Current report (foreign)
7:36am
6-K
EX-99.2
fd0qytsqughph aptmr
28 Jul 22
Current report (foreign)
7:36am
6-K
EX-99.1
jejwlabyo2c68fh545s
24 Jun 22
Current report (foreign)
5:29pm
6-K
EX-99.2
pw2wkh cqdd
28 Apr 22
Current report (foreign)
7:37am
6-K
EX-99.1
7thgqo59xfl2cg
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
6-K
EX-99.1
h2dj zjmmak
16 Mar 22
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
7:51am
6-K
EX-99.2
x7isqdqg6hpd064
8 Nov 21
Current report (foreign)
7:27am
6-K
EX-99.2
84peszwzi
4 Aug 21
Current report (foreign)
7:21am
6-K
EX-99.1
m0wjcq49gw8iws
27 Jul 21
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH
7:34am
6-K
EX-99.1
kgaljgxyd4sw6zdcovi0
25 Jun 21
Current report (foreign)
4:31pm
424B5
ycuswwiq a4lz4z49g3
5 May 21
Prospectus supplement for primary offering
4:47pm
6-K
EX-99.2
e0mn sowifxt
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am